Korean J Vet Res > Volume 61(2); 2021 > Article
Shin, Kim, Park, and Hahn: Clinical profile of Asian and African strains of Zika virus in immunocompetent mice


The mosquito-borne pathogen Zika virus may result in neurological disorders such as Guillain-Barré syndrome and microcephaly. The virus is classified as a member of the Flaviviridae family and its wide spread in multiple continents is a significant threat to public health. So, there is a need to develop animal models to examine the pathogenesis of the disease and develop vaccines. To examine the clinical profile during Zika virus infection, we infected neonatal and adult wild-type mice (C57BL/6 and Balb/c) and compared the clinical signs of African-lineage strain (MR766) and Asian-lineage strain (PRVABC59, MEX2-81) of Zika virus. Consistent with previous reports, eight-week-old female Balb/c mice infected with these viral strains showed changes in body weight, survival rate, and no neurologic signs, but demonstrated increases in the weights of spleens and hearts. However, one-day-old neonates showed significantly lower survival rate and body weight with the African-lineage strain than the Asian-lineage strain. These results confirmed the pathogenic differences between Zika virus strains. We also evaluated the clinical responses in neonatal and adult mice of different strains. Our findings suggest that these are useful mouse models for characterization of Zika virus for vaccine development.


Zika virus (ZIKV) is a mosquito-borne virus that was first isolated in 1947 from a febrile sentinel rhesus monkey in the Zika Forest in Uganda [1]. ZIKV belongs to the Flavivirus genus that is classified in the Flaviviridae family along with dengue virus (DENV), yellow fever virus, West Nile virus, and Japanese encephalitis virus. A single-strand positive-sense RNA virus, ZIKV, is composed of a 5′-UTR (~107 nucleotides), a 10.2 kb open reading frame (ORF), and a 3′-UTR (~428 nucleotides), giving a total genome of 11 kb. The ORF encodes three structural proteins (C, prM, and E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [2,3].
In the past, ZIKV infection was not regarded as a major threat to public health because it induced only mild clinical symptoms such as rash, fever, and headache [4]. However, in 2013, ZIKV began to attract attention as a massive outbreak occurred in French Polynesia [5,6]. In 2015, cases of severe ZIKV infection were reported in Brazil and other South American countries inducing Guillain-Barré syndrome and microcephaly in newborns [7-10]. In addition, ZIKV detection in nonserum body fluids such as semen, saliva, and urine suggests direct human-to-human infection [11,12]. As of mid-2019, ZIKV infection had spread to 87 countries and the Aedes aegypti vector detected in 61 countries. Despite the global spread of ZIKV, no effective vaccine has yet been developed [13].
ZIKV is classified into two main lineages, Asian or African, based on the phylogenetic classification of ORF sequences [14-16]. After the initial detection of ZIKV in Africa, Asian strains spread rapidly to the Pacific islands and the American continent in 2015 and 2016 [4,12,17-19]. The infectivity and pathogenicity of ZIKV are not understood fully, but studies suggest that the African-lineage strain tends to induce more fetal loss and fewer birth defects than the Asian-lineage strain [20,21]. At the amino acid level, the two lineages show differences in 75 to 100 residues of the 3,424 amino acid sequence. This difference between amino acid sequences makes a difference in virus phenotype. For example, SV0127-14 strain, which originated in Thailand, differs by five amino acids from the CPC-0740 strain originating in the Philippines; this difference results in phenotypic differences both in vitro and in vivo [22]. It is possible that susceptibility to ZIKV can be determined by the original mosquitoes vector (Aedes aegypti and Aedes albopictus): studies have shown that ZIKV transmitted via Brazilian mosquitoes was less infectious than strains transmitted by vectors in the Dominican Republic and the United States, which suggests that the virulence might be controlled by viral adaptation to the host [23,24].
Because ZIKV does not replicate efficiently in the presence of type I interferon (IFN), various ZIKV profiling studies have used immunocompromised mouse models such as A129 (type I IFN receptor knockout [KO]), interferon regulatory factor (IRF)3/5/7 triple KO, or AG129 (type I and II IFN KO) [25]. These mice models provide useful data, but these mice strains are limited in use compared to the wild type mice strains because they are expensive. Therefore, in our study, we utilized neonatal and adult immunocompetent mice to develop a mouse model which is less expensive and broad strange of application. And using these mouse models, we compared the virulence of Asian-lineage and African-lineage strain of ZIKV.

Materials and Methods


Balb/c (female, 8 weeks old) and C57BL/6 (female, 8 weeks old) mice were purchased from Orient Bio Inc. (Korea). Neonatal Balb/c and C57BL/6 mice (one day old) were bred from homozygous breeding pairs. Mice were housed in the Animal Laboratory Center of Kangwon National University under a 12-hour light-dark cycle and given free access to food and water. This work was approved by Institutional Animal Care and Use Committee of Kangwon National University (approval number: KW-180319-1).

ZIKV strains and cell culture

The following ZIKV strains provided by BEI Resources (Manassas, VA, USA) were used in this study: MR766 (BEI Resources No. NR-50065), PRVABC59 (BEI Resources No. NR-50240), and MEX2-81 (BEI Resources No. NR-50280) (Table 1). Sequences of these ZIKV strains were downloaded from NCBI PubMed and aligned using Basic Local Alignment Search Tool (BLAST) (Table 2). Vero and Vero 76 cell lines were purchased from the American Type Culture Collection (Bethesda, MD, USA). Vero cells were incubated in 5% CO2 at 37℃ using Minimum Essential Medium (MEM-α) (Gibco, USA) containing 10% fetal bovine serum (FBS) (GenDEPOT, USA) and Vero 76 cells (ATCC, CRL-1587) were incubated in 5% CO2 at 37℃ using Dulbecco’s Minimal Essential Medium (DMEM) (GenDEPOT) containing 10% FBS, until they formed monolayers. Vero cells were infected with PRVABC59 and MEX2-81 strain at a multiplicity of infection (MOI) of 0.01, and then incubated in MEM-α containing 2% FBS. Vero 76 cells were infected with MR766 strain at an MOI of 0.01 and incubated in DMEM containing 2% FBS. Viral samples were concentrated by ultrafiltration and purified using a Capto™ Core 700 column (GE Healthcare, Sweden). Titers of virus stocks were quantified by plaque assay of both cell lines.

ZIKV infection in mice

Eight-week-old Balb/c female mice were inoculated subcutaneously with each strain of ZIKV (MR766 or MEX2-81), or phosphate-buffered saline (PBS) as a negative control. Eight-week-old Balb/c female mice were inoculated subcutaneously with two strains of ZIKV (106.8 TCID50/mouse of MR766 or 106 TCID50/mouse of MEX2-81) or PBS as a negative control. One-day-old Balb/c and C57BL/6 mice were inoculated subcutaneously with each strain of ZIKV (106.8 TCID50/mouse of MR766, 106 TCID50/mouse of MEX2-81, or 106.3 TCID50/mouse of PRVABC59), or PBS as a negative control. Adult mice were monitored until 7 days post infection (dpi) to assess survival rate, weight loss, and abnormal behavior. At 7 dpi, mice were euthanized with CO2 and the weights of organs including heart, lung, liver, brain, and pancreas were measured. Neonatal mice were monitored until 20 dpi to assess survival rate, weight loss, and abnormal behavior. Animals were allocated a score (0-3) [22] based on the most severe clinical sign observed: normal appearance (0); staggering walk, wide stance, or paralysis of hind leg (1); 25% weight loss or labored breathing (2); death (3).

Plaque-forming unit assay

Vero and Vero 76 cells were infected with log dilutions of ZIKV (10-1 to 10-5 dilution) in MEM-α or DMEM containing 10% FBS followed by addition of a 1% agar overlay. After 5 to 7 days, cells were fixed with 8% buffered formalin (in PBS) and stained with 1% crystal violet. Measurements of plaque diameter were made using ImageJ software. Virus titers were calculated by multiplying the plaque count by the virus dilution and dividing by the infection volume, and expressed as plaque-forming units (PFU)/mL. Each sample was assayed in duplicate.

Statistical analyses

Statistical analysis was performed using GraphPad Prism (ver. 5.0; GraphPad Software, USA). The significance of changes in plaque diameter, and mouse body and organ weights were analyzed using one-way analysis of variance. A p-value < 0.05 was considered significant.


Genetic (phylogenetic) analyses and characterization of ZIKV in vitro

First, we evaluated the virulence of African-lineage strain (MR766) and Asian-lineage strain (MEX2-81, PRVABC59) (Table 1) and compared their nucleotide and amino acid sequences using BLAST alignment (Table 2). For the nucleotide sequence, the African-lineage strain showed approximately 89% similarity to the Asian-lineage strain, whereas the amino acid sequences were approximately 96% identical. As expected, more than 99% similarity was confirmed between the two Asian-lineage strain (Table 2). To examine whether the changes in sequence affected the basic phenotype, we evaluated the characteristics of each strain. When we infected Vero cells with serially diluted ZIKV, the African-lineage strain (MR766) induced a cytopathic effect (CPE) at 4 dpi while that for the Asian-lineage strain (PRVABC59, MEX2-81) CPE occurred 1 to 2 days later. Similarly, the African-lineage strain induced larger plaques (1.6 ± 0.6 mm) than the Asian-lineage strain (PRVABC59, 1.2 ± 0.5 mm; MEX2-81, 0.9 ± 0.2 mm) (Fig. 1). These findings confirmed that the African-lineage strain is more cytopathic than the Asian strains in vitro.

Clinical profile of ZIKV infection in adult mice

Next, we infected 8-week-old female Balb/c to evaluate ZIKA virulence in immunocompetent mice. Infected mice showed no loss in body weight, neurologic signs, pathology, or fatalities (Fig. 2A and B). This is consistent with the findings of previous studies that reported few clinical signs and low susceptibility in immunocompetent hosts. However, we observed a significant increase in spleen weight and size compared to the PBS inoculated group in infected immunocompetent mice, indicating an active immune response to ZIKV infection (Fig. 2C).

African lineage infection suppressed the growth of neonatal mice

Because the adult immunocompetent mice showed minor clinical signs but indications of an active immune response in lymphoid organs, we attempted to boost the systemic response by infecting neonatal mice in which the immune system had not yet developed. In both Balb/c and C57BL/6 neonates, infection with the African-lineage strain caused a decrease in body weight around 6 dpi and the mice died by 7 dpi. By contrast, Balb/c neonates infected with the Asian-lineage strain showed milder symptoms and all survived up to 20 dpi (Fig. 3A and C). However, C57BL/6 neonates infected with PRVABC59 showed a decrease in body weight from day 5 to day 10 with 40% mortality by 15 dpi; the MEX2-81 strain did not induce any clinical signs by 20 dpi (Fig. 3B and D). These results confirm that the African-lineage strain is more virulent than the Asian-lineage strain, and showed that C57BL/6 neonates were more susceptible than Balb/c neonates, which could be related to their more dominant T helper (Th)1 responses [26].

Clinical signs of Asian lineage infection in neonatal mice

Microcephaly is the main pathology induced by ZIKV when it attacks neural progenitor cells. This is associated with various neurological disorders because of abnormal neurogenesis, neuron development, and neural gene expression [27]. We evaluated the neurologic signs in infected mice. Balb/c neonates infected with MEX2-81 strain showed no clinical signs by 20 dpi, but C57BL/6 neonates infected with MEX2-81 strain, half showed neurologic symptoms such as hind leg paralysis by 13 dpi. Balb/c neonates infected with PRVABC59 strain showed symptoms including imbalance and a wide stance at around 10 dpi, but only one of those mice showed paralysis of hind leg after 11 dpi. However, C57BL/6 mice infected with PRVABC59 showed more severe neurologic signs and weight loss from 11 dpi, and 40% of infected neonates died by 15 dpi (Fig. 4). Although the impact of the Asian strain is minimal, our results suggest that Asian strains are also sufficiently virulent to cause significant clinical signs when they infect neonatal mice.


Continuous ZIKV outbreaks have been a public health issue for the last several decades, and the possibility of epidemic reemergence of ZIKV requires the development of a vaccine. Although a number of studies have suggested new vaccine strategies, it is still required to develop improved animal models for the accurate evaluation of such vaccines. Thus, our study suggests the possibility of a new, less complicated animal model for ZIKV evaluation. We infected adult and neonatal immunocompetent mice with Asian-lineage and African-lineage strain. Then, we observed their susceptibility and clinical signs in response to infection using different combinations of viral lineage, mouse strain, and mouse age.
In humans, the NS5 protein of ZIKV inhibits type I IFN responses by neutralizing signal transducer and activator of transcription (STAT) 2 signaling. However, this viral protein does not bind to mouse STAT2, thus allowing normal type I IFN responses [28]. Therefore, the majority of ZIKV profiling studies have used type I IFN-deficient mice such as A129 (type I IFNR KO), IRF 3/5/7 triple KO, and AG129 (type I and II IFN KO) [25]. These mice models provide useful data, but these mice strains are expensive and have narrow range of applications due to immunological defects.
The stage of central nervous system development in murine neonates is comparable with that of a human midterm fetus [29]. Furthermore, these neonates are very susceptible to infection with neurotropic viruses including Herpes, Borna virus, Tacaribe arenavirus, and chikungunya virus, which are associated with meningoencephalitis [30-33]. A previous report proposed an animal model to monitor clinical progression, virus distribution, neuropathology, and immune responses after Asian ZIKV infection of C57BL/6 neonates [25]. In the current study, we improved this mouse model by adding the Balb/c mouse strain and using both African-lineage and Asian-lineage strain. It is obvious that type I IFN-deficient mice develop severe clinical signs, but incomplete immunoregulatory mechanisms in these strains may skew our understanding of the pathophysiology of the disease due to impaired IFN response. In addition, previous studies on the pathology of flavivirus suggest that pathogenicity may be determined not only by the effect of the virus but also by the immune response elicited by the virus [32,34]. Therefore, characterizing the clinical changes occurring in immunocompetent hosts will clarify the pathogenic mechanism of ZIKV [26].
Consistent with the findings of previous studies, we observed no significant changes in body weight, survival rates, and neurologic signs when adult mice were infected with various ZIKV strains. However, we observed that the infection resulted in increased weight and size of hearts and spleens. Infection with other arboviruses such as chikungunya virus and DENV induced myocardial effects, and it is possible that ZIKV also invaded cardiac cells [35]. In addition, the increase in splenic size suggests the occurrence of an active immune response in adult mice, even those without clinical signs or changes in body weight. It would be informative to investigate the presence of virus in their peripheral tissues.
Next, we compared the susceptibility of mice to African-lineage and Asian-lineage strain of ZIKV by infecting neonatal mice in which development of the immune system is incomplete. Previous studies reported higher levels of birth defects and fetal loss from infection with African-lineage strain compared with the Asian-lineage strain, which might indicate greater pathogenesis during pregnancy [20,21]. Consistent with this, our results show that the African-lineage strain (MR766) affected all mice but that the Asian-lineage strain (PRVABC59 and MEX2-81) did not affect survival rates, although they induced neurologic symptoms. This means that the African-lineage strain (MR766) is highly virulent and pathogenic strain compared to the Asian-lineage strain (PRVABC59 andMEX2-81) in mice models. Also, our studies are in line with previous observations that ZIKV induces a neurodestructive inflammatory response by activation of cerebral cytotoxic CD8+ T cells [25].
It has been suggested that the amino acid sequence of ZIKV can determine its pathogenicity and virulence. A recent study of the ZIKV/Hu/S36/Ciba/2016 strain reported that the size of plaques was affected by changes in amino acid sequences. For example, viruses with adenine at position 796 (230Gln) formed small plaques but if adenine was replaced with guanine (230Arg), this induced large plaques [36]. The three ZIKV strains used in our study are all 230Arg, but it is possible that the 3.2% to 3.4% variation in amino acid sequence changed viral growth and plaque size. Thus, we speculate that the amino acid modifications were responsible for the differential clinical effects, such as mortality seen with the African-lineage strain and the neurologic signs caused by the Asian-lineage strain. Therefore, a deeper understanding of genetic modulation in ZIKV is essential for vaccine improvement.
In conclusion, our infection model can be applied to investigate the nature of immune responses during ZIKV infection and provide useful information for both vaccine development and selection of challenge strains.


The authors declare no conflict of interest.


This research was supported by funding from the Korea Centers for Disease Control and Prevention (2016-ER4203-02). We also would like to thank Eunjin Hong for providing technical assistance.

Fig. 1.
Plaque phenotype of African and Asian Zika virus isolates in Vero cell monolayers (A). Plaque phenotype was assessed in Vero cell monolayers 5 days post infection (dpi). Cells were fixed and stained with crystal violet. Measurements of plaque diameter were made using ImageJ software (B). Statistical analysis **p < 0.01, ***p < 0.001. CPE, cytopathic effect; PFU, plaque-forming unit.
Fig. 2.
Clinical profiling of Zika virus infection in adult mice. (A-C) Eight-week-old Balb/c mice (n = 5 per group) were inoculated with 106.8 TCID50/mouse of MR766 or 106 TCID50/mouse of MEX2-81 strain. To measure weight loss (A) and survival (B), animals were monitored until 7 days post infection (dpi). Mice were autopsied at 7 dpi and their organ weights measured (C). Statistical analysis *p < 0.05, **p < 0.01, ***p < 0.001. PBS, phosphate-buffered saline.
Fig. 3.
The survival rate and body weight of neonatal mice infected with Zika virus. The survival rate and body weight of one-day-old Balb/c (A, C) and C57BL/6 (B, D) neonatal mice (n = 3-5 per group) were monitored until 20 days post infection (dpi). One-day-old neonatal mice were inoculated with 106.8 TCID50/mouse of MR766 strain or 106 TCID50/mouse of MEX2-81 strain or 106.3 TCID50/mouse of PRVABC59 strain. Statistical analysis *p < 0.05, **p < 0.01, ***p < 0.001. PBS, phosphate-buffered saline.
Fig. 4.
Clinical score of neonatal mice infected with Zika virus. Mice were allocated a clinical score (0-3) based on the most severe clinical sign observed. Normal appearance (0); staggering walk, wide stance, or paralysis of hind leg (1); 25% weight loss or labored breathing (2); death (3). PBS, phosphate-buffered saline; dpi, days post infection.
Table 1.
Zika virus strains used in this study
Location Isolate CPE (day) Titer (PFU/mL) TCID50/mL Inoculation dose (TCID50/mouse)
African lineage Uganda MR766 4 3.5 × 107 107.8 106.8
Asian lineage Mexico MEX2-81 6 5 × 105 108 106
Puerto Rico PRVABC59 5 4 × 106 108.3 106.3

CPE, cytopathic effect; PFU, plaque-forming unit.

Table 2.
Alignment of African and Asian Zika virus isolates
Isolate MR766 MEX2-81 PRVABC59
African lineage MR766 89.1* 89
Asian lineage MEX2-81 96.8* 99.6
PRVABC59 96.6* 99.7*

* Nucleotide comparison below the diagonal.

Amino acid comparison above the diagonal.


1. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952;46:509-520.
crossref pmid
2. Fields BN, Knipe DM, Howley PM. Fields Virology. 6th ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, 2013.
3. Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res 2003;59:23-61.
crossref pmid
4. Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev 2016;29:487-524.
crossref pmid pmc
5. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V, Halstead SK, Willison HJ, Musset L, Manuguerra JC, Despres P, Fournier E, Mallet HP, Musso D, Fontanet A, Neil J, Ghawché F. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016;387:1531-1539.
crossref pmid pmc
6. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, Sall AA, Musso D. Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis 2014;20:1085-1086.
crossref pmid pmc
7. Paploski IA, Prates AP, Cardoso CW, Kikuti M, Silva MM, Waller LA, Reis MG, Kitron U, Ribeiro GS. Time lags between exanthematous illness attributed to Zika virus, Guillain-Barre syndrome, and microcephaly, Salvador, Brazil. Emerg Infect Dis 2016;22:1438-1444.
crossref pmid pmc
8. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36:123-133.
crossref pmid pmc
9. World Health Organization (WHO). Zika situation reports [Internet]. WHO; Geneva: [updated 2016; cited 2021]. Available from: https://apps.who.int/iris/handle/10665/246155.
10. World Health Organization (WHO). WHO Director-General summarizes the outcome of the emergency committee regarding clusters of microencephaly and Gullain Barre Syndrome [Internet]. WHO; Geneva: [updated 2016; cited 2021]. Available from: https://www.who.int/news/item/01-02-2016-who-director-general-summarizes-the-outcome-of-the-emergency-committee-regarding-clusters-of-microcephaly-and-guillain-barr%C3%A9-syndrome.
11. Likos A, Griffin I, Bingham AM, Stanek D, Fischer M, White S, Hamilton J, Eisenstein L, Atrubin D, Mulay P, Scott B, Jenkins P, Fernandez D, Rico E, Gillis L, Jean R, Cone M, Blackmore C, McAllister J, Vasquez C, Rivera L, Philip C. Local mosquito-borne transmission of Zika virus - Miami-Dade and Broward Counties, Florida, June-August 2016. MMWR Morb Mortal Wkly Rep 2016;65:1032-1038.
crossref pmid
12. Metsky HC, Matranga CB, Wohl S, Schaffner SF, Freije CA, Winnicki SM, West K, Qu J, Baniecki ML, Gladden-Young A, Lin AE, Tomkins-Tinch CH, Ye SH, Park DJ, Luo CY, Barnes KG, Shah RR, Chak B, Barbosa-Lima G, Delatorre E, Vieira YR, Paul LM, Tan AL, Barcellona CM, Porcelli MC, Vasquez C, Cannons AC, Cone MR, Hogan KN, Kopp EW, Anzinger JJ, Garcia KF, Parham LA, Ramírez RMG, Montoya MCM, Rojas DP, Brown CM, Hennigan S, Sabina B, Scotland S, Gangavarapu K, Grubaugh ND, Oliveira G, Robles-Sikisaka R, Rambaut A, Gehrke L, Smole S, Halloran ME, Villar L, Mattar S, Lorenzana I, Cerbino-Neto J, Valim C, Degrave W, Bozza PT, Gnirke A, Andersen KG, Isern S, Michael SF, Bozza FA, Souza TML, Bosch I, Yozwiak NL, MacInnis BL, Sabeti PC. Zika virus evolution and spread in the Americas. Nature 2017;546:411-415.
crossref pmid pmc
13. World Health Organization (WHO). Countries and territo­ries with current or previous Zika virus transmission [internet]. WHO; Geneva: 2019 [updated 2019; cited 2020 Jul 22]. Available from: https://www.who.int/emergencies/diseases/zika/countries-with-zika-and-vectors-table.pdf.
14. Faye O, Freire CC, Iamarino A, Faye O, de Oliveira JV, Diallo M, Zanotto PM, Sall AA. Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl Trop Dis 2014;8:e2636.
crossref pmid pmc
15. Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V, Huy R, Guzman H, Tesh RB, Weaver SC. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl Trop Dis 2012;6:e1477.
crossref pmid pmc
16. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield SM, Duffy MR. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 2008;14:1232-1239.
crossref pmid pmc
17. Pettersson JH, Bohlin J, Dupont-Rouzeyrol M, Brynildsrud OB, Alfsnes K, Cao-Lormeau VM, Gaunt MW, Falconar AK, de Lamballerie X, Eldholm V, Musso D, Gould EA. Re-visiting the evolution, dispersal and epidemiology of Zika virus in Asia. Emerg Microbes Infect 2018;7:79.
crossref pmid pmc
18. Liu ZY, Shi WF, Qin CF. The evolution of Zika virus from Asia to the Americas. Nat Rev Microbiol 2019;17:131-139.
crossref pmid
19. Hu T, Li J, Carr MJ, Duchêne S, Shi W. The Asian lineage of Zika virus: transmission and evolution in Asia and the Americas. Virol Sin 2019;34:1-8.
crossref pmid pmc
20. Sheridan MA, Balaraman V, Schust DJ, Ezashi T, Roberts RM, Franz AWE. African and Asian strains of Zika virus differ in their ability to infect and lyse primitive human placental trophoblast. PLoS One 2018;13:e0200086.
crossref pmid pmc
21. Duggal NK, Ritter JM, McDonald EM, Romo H, Guirakhoo F, Davis BS, Chang GJ, Brault AC. Differential neurovirulence of African and Asian genotype Zika virus isolates in outbred immunocompetent mice. Am J Trop Med Hyg 2017;97:1410-1417.
crossref pmid pmc
22. Smith DR, Sprague TR, Hollidge BS, Valdez SM, Padilla SL, Bellanca SA, Golden JW, Coyne SR, Kulesh DA, Miller LJ, Haddow AD, Koehler JW, Gromowski GD, Jarman RG, Alera MTP, Yoon IK, Buathong R, Lowen RG, Kane CD, Minogue TD, Bavari S, Tesh RB, Weaver SC, Linthicum KJ, Pitt ML, Nasar F. African and Asian Zika Virus Isolates display phenotypic differences both in vitro and in vivo. Am J Trop Med Hyg 2018;98:432-444.
crossref pmid
23. Roundy CM, Azar SR, Rossi SL, Huang JH, Leal G, Yun R et al. Variation in Aedes aegypti mosquito competence for Zika virus transmission. Emerg Infect Dis 2017;23:625-632.
crossref pmid pmc
24. Simonin Y, van Riel D, Van de Perre P, Rockx B, Salinas S. Differential virulence between Asian and African lineages of Zika virus. PLoS Negl Trop Dis 2017;11:e0005821.
crossref pmid pmc
25. Manangeeswaran M, Ireland DD, Verthelyi D. Zika (PRVABC59) infection is associated with T cell infiltration and neurodegeneration in CNS of immunocompetent neonatal C57Bl/6 Mice. PLoS Pathog 2016;12:e1006004.
crossref pmid pmc
26. Yu J, Liu X, Ke C, Wu Q, Lu W, Qin Z, He X, Liu Y, Deng J, Xu S, Li Y, Zhu L, Wan C, Zhang Q, Xiao W, Xie Q, Zhang B, Zhao W. Effective suckling C57BL/6, Kunming, and BALB/c mouse models with remarkable neurological manifestation for Zika virus infection. Viruses 2017;9:165.
crossref pmid pmc
27. Faizan MI, Abdullah M, Ali S, Naqvi IH, Ahmed A, Parveen S. Zika virus-induced microcephaly and its possible molecular mechanism. Intervirology 2016;59:152-158.
crossref pmid
28. Gorman MJ, Caine EA, Zaitsev K, Begley MC, Weger-Lucarelli J, Uccellini MB, Tripathi S, Morrison J, Yount BL, Dinnon KH 3rd, Rückert C, Young MC, Zhu Z, Robertson SJ, McNally KL, Ye J, Cao B, Mysorekar IU, Ebel GD, Baric RS, Best SM, Artyomov MN, Garcia-Sastre A, Diamond MS. An immunocompetent mouse model of Zika virus infection. Cell Host Microbe 2018 23:672-685. e6.
crossref pmid pmc
29. Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble-Haeusslein LJ. Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Prog Neurobiol 2013;106-107:1-16.
crossref pmid
30. Pletnikov MV, Rubin SA, Moran TH, Carbone KM. Exploring the cerebellum with a new tool: neonatal Borna disease virus (BDV) infection of the rat's brain. Cerebellum 2003;2:62-70.
crossref pmid
31. Amstey MS, Kobos K. An experimental model for disseminated herpesvirus infection of the neonate. Am J Obstet Gynecol 1976;125:40-44.
crossref pmid
32. Pedras-Vasconcelos JA, Puig M, Sauder C, Wolbert C, Ovanesov M, Goucher D, Verthelyi D. Immunotherapy with CpG oligonucleotides and antibodies to TNF-alpha rescues neonatal mice from lethal arenavirus-induced meningoencephalitis. J Immunol 2008;180:8231-8240.
crossref pmid
33. Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Desprès P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 2008;4:e29.
crossref pmid pmc
34. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-177.
crossref pmid
35. Obeyesekere I, Hermon Y. Arbovirus heart disease: myocarditis and cardiomyopathy following dengue and chikungunya fever--a follow-up study. Am Heart J 1973;85:186-194.
crossref pmid
36. Kato F, Tajima S, Nakayama E, Kawai Y, Taniguchi S, Shibasaki K, Taira M, Maeki T, Lim CK, Takasaki T, Saijo M. Characterization of large and small-plaque variants in the Zika virus clinical isolate ZIKV/Hu/S36/Chiba/2016. Sci Rep 2017;7:16160.
crossref pmid pmc

Browse articles
For contributors
Editorial Office
#401-1, 85 Bldg., College of Veterinary Medicine, Seoul National University
1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea
Tel: +82-2-880-1229    Fax: +82-2-878-9762    E-mail: jvs@ksvs.or.kr                

Copyright © 2024 by The Korean Society of Veterinary Science.

Developed in M2PI

Close layer
prev next